Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran.
USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran.
ACS Chem Neurosci. 2021 Dec 15;12(24):4475-4490. doi: 10.1021/acschemneuro.1c00540. Epub 2021 Nov 27.
The blood-brain barrier (BBB) is considered as the most challenging barrier in brain drug delivery. Indeed, there is a definite link between the BBB integrity defects and central nervous systems (CNS) disorders, such as neurodegenerative diseases and brain cancers, increasing concerns in the contemporary era because of the inability of most therapeutic approaches. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have already been identified as having several advantages in facilitating the transportation of hydrophilic and hydrophobic agents across the BBB. This review first explains BBB functions and its challenges in brain drug delivery, followed by a brief description of nanoparticle-based drug delivery for brain diseases. A detailed presentation of recent progressions in optimizing SLNs and NLCs for controlled release drug delivery, gene therapy, targeted drug delivery, and diagnosis of neurodegenerative diseases and brain cancers is approached. Finally, the problems, challenges, and future perspectives in optimizing these carriers for potential clinical application were described briefly.
血脑屏障(BBB)被认为是脑内药物递送中最具挑战性的屏障。事实上,BBB 完整性缺陷与中枢神经系统(CNS)疾病之间存在明确的联系,如神经退行性疾病和脑癌,由于大多数治疗方法都无能为力,这在当代引起了更多的关注。固体脂质纳米粒(SLNs)和纳米结构脂质载体(NLCs)已被确定为具有多种优势,可促进亲水性和疏水性药物穿过 BBB。本综述首先解释了 BBB 的功能及其在脑内药物递送中的挑战,接着简述了基于纳米颗粒的脑部疾病药物递送。详细介绍了为控制释放药物递送、基因治疗、靶向药物递送以及神经退行性疾病和脑癌的诊断而对 SLNs 和 NLCs 进行优化的最新进展。最后,简要描述了优化这些载体以用于潜在临床应用的问题、挑战和未来展望。